The effects of curcumin supplementation added to diet on anthropometric and biochemical status in women with polycystic ovary syndrome: A randomized, placebo-controlled trial

Main Article Content

Sabiha Ataç Asan
Murat Baş
Berna Eren
Esen Karaca


Polycystic ovary syndrome (PCOS), curcumin, obesity, insulin resistance, hyperlipidemia


Clinical manifestations of polycystic ovary syndrome (PCOS) include infrequent or absent menses, abdominal obesity, acanthosis nigricans and signs of androgen excess which include acne or seborrhea and insulin resistance. We hypothesized that curcumin added to diet would modulate anthropometric and biochemical status in women with PCOS.  This study was performed with the participation of 30 individuals diagnosed with PCOS by physicians. Participants were randomly assigned to curcumin (at a dose of 93.34 mg) or placebo groups.  After a period of eight weeks,  body weight, body fat mass and waist circumferences (WC) were found  lower in the curcumin group than the placebo group (p<0.05).  Body weight decreased by 5.8 ± 2.3 kg after intervention in curcumin group (p<0.05) and 3.2 ± 2.5 kg in placebo group (p<0.05).  In addition, waist circumferences decreased by 7.2 ± 3.5 cm after intervention in curcumin group (p<0.05) and 4.1 ± 2.1 cm in placebo group (p<0.05).  Between-group difference analysis showed that there were significant differences in fasting blood glucose levels, fasting insulin levels, homeostasis model assessment for insulin resistance (HOMA-IR) and C-reactive protein (CRP) levels in curcumin group (p<0.05).  On the other hand, between-group difference analysis showed no significant differences in lipid parameters (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels) and hormone levels (p>0.05).  These results indicated that curcumin supplementation added to diet in women with PCOS improved the anthropometric measurements and glysemic parameters; however did not restore the hormone and lipid profiles.


Download data is not yet available.
Abstract 670 | PDF Downloads 233


1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis, and treatment. Nature Reviews Endocrinology 2018; 14: 270–284.
2. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction 2016; 31(12): 2841–2855.
3. Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update 2018; 24(4): 455–467.
4. Reddy PS, Begum N, Mutha S, Bakshi V. Beneficial effect of curcumin in Letrozole induced polycystic ovary syndrome. Asian Pacific Journal of Reproduction 2016; 5(2): 116-122.
5. Baysal B. Polikistik over sendromu ve hirsutizm. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Sempozyum Dizisi 2008; 63: 99-107.
6. Moghetti P, Carmina E, De Leo V, et al. How to manage the reproductive issues of PCOS: A 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. Journal of Endocrinological Investigation 2015; 38(9): 1025-1037.
7. Mirzaei H, Masoudifar A, Sahebkar A, et al. MicroRNA: A novel target of curcumin in cancer therapy. Journal of Cellular Physiology 2018; 233: 3004-3015.
8. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. The Journal of Nutrition 2001; 131(11): 2932–2935.
9. Priyadarsini KI. The chemistry of curcumin: From extraction to therapeutic agent. Molecules 2014; 19(12): 20091-20112.
10. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annual Review of Nutrition 2010; 30: 173-199.
11. Bradford PG. Curcumin and obesity. Biofactors 2013; 39(1): 78-87.
12. Joint FAO/WHO Expert Committee on Food Additives (‎1998 : Geneva, Switzerland)‎, World Health Organization & Food and Agriculture Organization of the United Nations. (‎2000)‎. Evaluation of certain food additives : fifty-first report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization.
13. Liddle M, Hull C, Liu C, Powell D. Contact urticaria from curcumin. Dermatitis 2006; 17(4): 196–197.
14. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008; 14(14): 4491–4499.
15. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. Journal of the American Association of Pharmaceutical Scientists 2013; 15(1): 195-218.
16. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004; 19: 41–47.
17. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. SpringerPlus 2013; 2: 56.
18. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clinical Endocrinology 2000; 52(1): 81–86.
19. Na LX, Li Y, Pan HZ, et al. Curcuminoids exert glucose‐lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double‐blind, placebo‐controlled trial. Molecular Nutrition & Food Research 2013; 57: 1569–1577.
20. Román-Ramos R, Flores-Sáenz JL, Partida-Hernández G, Lara-Lemus A, Alarcón-Aguilar F. Experimental study of the hypoglycemic effect of some antidiabetic plants. Archives of Investigative Medicine (Mex) 1991; 22: 87–93.
21. Sohaei S, Amani R, Tarrahi MJ, Ghasemi-Tehrani H. The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. Complementary Therapies in Medicine 2019; 47: 102201.
22. Kocher A, Bohnert L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Molecular Nutrition & Food Research 2016; 60(7): 1555–1563.
23. Kádasi A, Sirotkin AV, Maruniaková N, Kolesárová A, Bulla J, Grossmann R. The effect of curcumin on secretory activity, proliferation and apoptosis of the porcine ovarian granulosa cells. Journal of Microbiology, Biotechnology and Food Sciences 2010; 2(1): 349.
24. Park K, Kim J, Ahn C, Song Y, Lim S, Lee H. Polycystic ovarian syndrome (PCOS) and insulin resistance. International Journal of Gynecology & Obstetrics 2001; 74(3): 261–267.
25. Rouse M, Younès A, Egan JM. Resveratrol and curcumin enhance pancreatic β‐cell function by inhibiting phosphodiesterase activity. J. Endocrinol. 2014; 223: 107–117.
26. Naijil G, Anju TR, Jayanarayanan S, Paulose CS. Curcumin pretreatment mediates antidiabetogenesis via functional regulation of adrenergic receptor subtypes in the pancreas of multiple low‐dose streptozotocin‐induced diabetic rats. Nutrition Research 2015; 35: 823–833.
27. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods for Human Nutrition 2002; 57: 41–52.
28. Kim T, Davis J, Zhang AJ, He X, Mathews ST. Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochemical and Biophysical Research Communications 2009; 388: 377–382.
29. Tang Y,Chen A. Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter‐4 and increasing glucokinase. British Journal of Pharmacology 2010; 161: 1137–1149.
30. Chuengsamarna S, Rattanamongkolgulb S, Phonratc B, Tungtrongchitrd R, Jirawatnotaie S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. The Journal of Nutritional Biochemistry 2014; 25: 144–150.
31. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor‐β and interleukin‐8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double‐blind and placebo‐controlled study. Scandinavian Journal of Urology and Nephrology 2011; 45: 365–370.
32. Jiménez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance- Molecular targets and clinical evidences. BioFactors (Oxford, England) 2016; 42(6): 561–580.
33. Hariri M, Haghighatdoost F. Effect of curcumin on anthropometric measures: A systematic review on randomized clinical trials. Journal of the American College of Nutrition 2018; 37(3): 215–222.
34. Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: Preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. European Review for Medical and Pharmacological Sciences 2015; 19(21): 4195–4202.
35. Akbari M, Lankarani KB, Tabrizi R, et al. The Effects of Curcumin on Weight Loss Among Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 2019; 10: 649.
36. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytotherapy Research 2013; 27 (3): 374–379.
37. Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Molecular Nutrition & Food Research 2011; 55(12): 1829-1840.
38. Moohebati M, Yazdandoust S, Sahebkar A, et al. Investigation of the effect of short-term supplementation with curcuminoids on circulating small dense low-density lipoprotein concentrations in obese dyslipidemic subjects: A randomized double-blind placebo-controlled cross-over trial. ARYA Atherosclerosis 2014; 10(5): 280–286.
39. Sahebkar AA. Systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clinical Nutrition 2014; 33(3): 406-414.
40. Karbalay-Doust S, Noorafshan A. Ameliorative effects of curcumin on the spermatozoon tail length, count, motility and testosterone serum level in metronidazole-treated mice. Prague Medical Report 2011; 112(4): 288-297.
41. Tiwari-Pandey R, Ram Sairam M. Modulation of Ovarian Structure and Abdominal Obesity in Curcumin- and Flutamide-treated Aging FSH-R Haploinsufficient Mice. Reproductive Sciences 2009; 16(6): 539–550.
42. Giannessi F, Giambelluca MA, Grasso L, Scavuzzo MC, Ruffoli R. Curcumin protects Leydig cells of mice from damage induced by chronic alcohol administration. Medical Science Monitor 2008; 14: BR237–BR242.
43. Seyeddamoon S. Investigation the effect of curcumin on the hormones of pituitary-ovarian axis in alloxan-induced diabetic rats. Journal of Ardabil University of Medical Sciences 2016; 16(4): 441-451.
44. Rashmi TP, Sairam MR. Modulation of ovarian structure and abdominal obesity in curcumin-and flutamide-treated aging FSH-R haploinsufficient mice. Reproductive Sciences 2009; 16(6): 539-550.
45. Inano H, Onoda M, Inafuku N, et al. Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with γ-rays. Carcinogenesis 1999; 20(6): 1011-1018.
46. Aktas C, Kanter M, Erboga M, Ozturk S. Anti-apoptotic effects of curcumin on cadmium-induced apoptosis in rat testes. Toxicology and Industrial Health 2012; 28(2): 122-130.